menu ☰
menu ˟

FDA grants breakthrough therapy designation for Mydicar

12 Apr 2014
Celladon Corp. has announced that the FDA granted breakthrough therapy designation for Mydicar, a treatment for patients with chronic HF as a result of systolic dysfunction.According to a company press release, the novel, first-in-class genetic enzym...

Click here to view the full article which appeared in Cardiology

IPH Logo